Characteristics of patients given chemotherapy alone
Patient no. . | FAB classification . | Sex . | Age at diagnosis, y . | Cytogenetic/genetic anomalies . | WBC count at diagnosis, × 109/L . | First-line chemotherapy . | Outcome (+ mo elapsed from diagnosis) . |
|---|---|---|---|---|---|---|---|
| 1 | M3 | M | 8 | t(15; 17) | 1.8 | *ATRA + IDA; ARA-C + IDA; MTZ + VP-16 ARA-C + IDA + 6-TG | A&W (+74) |
| 2 | M4 | F | 3 | inv(16) | 105 | ICE (3 + 5 + 10) × 2; AVE; HAM | Relapsed (+5). Died after unrelated donor BMT |
| 3 | M3 | F | 6 | PML/RARα fusion transcript | 2.7 | *ATRA + IDA; ARA-C + IDA; MTZ + VP-16 ARA-C + IDA + 6-TG | Relapsed (+13). A&W (+26) after unrelated donor BMT |
| 4 | M2 | M | 13 | t(8;21) | 12.8 | ICE (3 + 5 + 10) × 2; AVE; HAM; HD-ARA-C | Relapsed (+17). A&W (+7) after unrelated donor BMT |
| 5 | M2 | M | 11 | t(8;21) | 15 | ICE (3 + 5 + 10) × 2; AVE; HAM; HD-ARA-C | A&W (+38) |
Patient no. . | FAB classification . | Sex . | Age at diagnosis, y . | Cytogenetic/genetic anomalies . | WBC count at diagnosis, × 109/L . | First-line chemotherapy . | Outcome (+ mo elapsed from diagnosis) . |
|---|---|---|---|---|---|---|---|
| 1 | M3 | M | 8 | t(15; 17) | 1.8 | *ATRA + IDA; ARA-C + IDA; MTZ + VP-16 ARA-C + IDA + 6-TG | A&W (+74) |
| 2 | M4 | F | 3 | inv(16) | 105 | ICE (3 + 5 + 10) × 2; AVE; HAM | Relapsed (+5). Died after unrelated donor BMT |
| 3 | M3 | F | 6 | PML/RARα fusion transcript | 2.7 | *ATRA + IDA; ARA-C + IDA; MTZ + VP-16 ARA-C + IDA + 6-TG | Relapsed (+13). A&W (+26) after unrelated donor BMT |
| 4 | M2 | M | 13 | t(8;21) | 12.8 | ICE (3 + 5 + 10) × 2; AVE; HAM; HD-ARA-C | Relapsed (+17). A&W (+7) after unrelated donor BMT |
| 5 | M2 | M | 11 | t(8;21) | 15 | ICE (3 + 5 + 10) × 2; AVE; HAM; HD-ARA-C | A&W (+38) |
FAB indicates French-American-British classification; WBC, white blood cell; A&W, alive and well; ICE, idarubicin 12 mg/m2/d 60-minute infusion on days 1, 3, 5; etoposide 100 mg/m2/d 1-hour intravenous (IV) infusion on days 1-5; cytarabine 25 mg/m2/d IV push on day 1 followed by 100 mg/m2/d continuous IV infusion on days 1-10; AVE, high-dose cytarabine 3 g/m2 3-hour infusion every 12 hours and etoposide 125 mg/m2/d 1-hour IV infusion for 4 days; HAM, high-dose cytarabine 3 g/m2 3-hour infusion every 12 hours for 3 days and mitoxantrone 10 mg/m2 60-minute infusion for 2 days; HD-ARA-C, high-dose cytarabine 3 g/m2 3-hour infusion every 12 hours for 3 days.
Induction therapy consisted of oral all-trans-retinoic acid (ATRA) 25 mg/m2/d, divided into 2 doses administered every 12 hours, up to hematologic remission and for a maximum of 90 days, and 4 brief intravenous infusions of idarubicin (IDA) 12 mg/m2 on days 2, 4, 6, and 8. Patients in hematologic complete remission (HCR) received 3 monthly consolidation courses consisting of cytosine arabinoside (ARA-C) 1000 mg/m2/d by IV infusion over 6 hours on days 1, 2, 3, and 4 and IDA 5 mg/m2/d by brief IV infusion on days 1, 2, 3, and 4, 3 hours after the end of the ARA-C infusion (course 1); mitoxantrone (MTZ) 10 mg/m2/d by brief IV infusion on days 1, 2, 3, 4, and 5 and etoposide (VP-16) 100 mg/m2/d by IV infusion lasting 45-60 minutes on days 1, 2, 3, 4, and 5 (12 hours after the start of MTZ) (course 2); IDA 12 mg/m2 IV infusion on day 1, ARA-C 150 mg/m2 every 8 hours given subcutaneously on days 1, 2, 3, 4, and 5, and 6-thioguanine (6-TG) 70 mg/m2 every 8 hours on days 1, 2, 3, 4, and 5 (course 3).